VolitionRx Extends Agreement with University Hospital Bonn to Include CE Mark Performance Evaluation

News   Apr 24, 2014

 
VolitionRx Extends Agreement with University Hospital Bonn to Include CE Mark Performance Evaluation
 
 
 
 

RELATED ARTICLES

CRISPR Reveals New Targets for Promising Cancer Drugs

News

Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.

READ MORE

Potential Barcode Identified for a Form of Alcoholic Liver Disease

News

NIAAA-supported researchers have discovered that extracellular vesicles released by liver cells in a mouse model of alcoholic steatohepatitis contain a miRNA signature detectable in the blood.

READ MORE

Enterome and Nestlé Health Sciences Launch New Diagnostics Company

News

Enterome and Nestlé Health Sciences join to create Microbiome Diagnostics Partners, a company that will enable the development and diagnostics for multiple diseases including inflammatory bowel diseases (IBD) and liver diseases.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE